TLR9 and systemic lupus erythematosus: Hydroxychloroquine, as shown by Sacre and colleagues, could reduce the capacity of pDCs in producing IFN-α and TNF-α upon in vitro stimulation with TLR9 and TLR7 agonists in SLE patients [31].